Expert Opinion on Investigational Drugs

Molecular biological design of novel antineoplastic therapies
pp. 577-607(31)
Authors: Vulfovich M.; Saba N.

Novel targeted agents in the treatment of lung cancer
pp. 609-629(21)
Authors: Saba N.; Khuri F.

Colon cancer angiogenesis and antiangiogenic therapy
pp. 631-641(11)
Authors: Wray C.J.; Rilo H.L.; Ahmad S.A.

Recent advances in natriuretic peptides in congestive heart failure
pp. 643-652(10)
Authors: Boerrigter G.; Burnett Jr J.C.

The potential of Na+/Ca2+ exchange blockers in the treatment of cardiac disease
pp. 653-664(12)
Authors: Hobai I.A.; O’Rourke B.

Novel approaches to antifungal prophylaxis
pp. 665-672(8)
Author: Ostrosky-Zeichner L.

Immunotherapeutics for nosocomial infections
pp. 673-679(7)
Author: Patti J.M.

Vaccines for the prevention of respiratory viral infections: problems and current status
pp. 681-689(9)
Authors: Olszewska W.; Helson R.; Openshaw P.J.

Cataract formation and prevention
pp. 691-701(11)
Author: Shichi H.

Vascular biology support for the use of bevacizumab in colorectal cancer
pp. 703-705(3)
Author: Doggrell S.A.

Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials
pp. 707-713(7)
Author: Salam A.M.

Antibacterial Drug Discovery & Development Summit
pp. 715-721(7)
Authors: Barrett J.F.; Dougherty T.J.